Holmium-166 Transarterial Radioembolization for the Treatment of Intrahepatic Cholangiocarcinoma: A Case Series.
holmium
intrahepatic cholangiocarcinoma
safety
selective internal radiation therapy (SIRT)
transarterial radioembolization (TARE)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Sep 2023
29 Sep 2023
Historique:
received:
17
08
2023
revised:
20
09
2023
accepted:
26
09
2023
medline:
14
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Transarterial radioembolization (TARE) is used to treat primary and secondary malignancies in the liver that are not amenable to curative resection. Accumulating evidence demonstrates the efficacy and safety of TARE with yttrium-90 ( This was a retrospective case series study of seven consecutive patients with ICC who were treated with Three out of the seven patients had a partial or complete response. Two patients had stable disease after the first TARE procedure, and two of the patients (one with a complete response, and one with stable disease) were alive at the time of analysis. No serious adverse events related to the procedure were recorded. This is the first case series reporting the safety and tumor response outcomes of
Sections du résumé
BACKGROUND
BACKGROUND
Transarterial radioembolization (TARE) is used to treat primary and secondary malignancies in the liver that are not amenable to curative resection. Accumulating evidence demonstrates the efficacy and safety of TARE with yttrium-90 (
METHODS
METHODS
This was a retrospective case series study of seven consecutive patients with ICC who were treated with
RESULTS
RESULTS
Three out of the seven patients had a partial or complete response. Two patients had stable disease after the first TARE procedure, and two of the patients (one with a complete response, and one with stable disease) were alive at the time of analysis. No serious adverse events related to the procedure were recorded.
CONCLUSIONS
CONCLUSIONS
This is the first case series reporting the safety and tumor response outcomes of
Identifiants
pubmed: 37835485
pii: cancers15194791
doi: 10.3390/cancers15194791
pmc: PMC10571855
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Terumo (Belgium)
ID : Open acces fee
Références
Cancers (Basel). 2023 Feb 15;15(4):
pubmed: 36831586
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1682-1699
pubmed: 35146577
Adv Radiat Oncol. 2022 Mar 21;7(4):100948
pubmed: 35814852
Clin Exp Metastasis. 2020 Feb;37(1):95-105
pubmed: 31732841
Ann Surg Oncol. 2022 Sep;29(9):5462-5473
pubmed: 35657463
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1965-75
pubmed: 24819055
J Nucl Med. 2013 Dec;54(12):2093-100
pubmed: 24136931
Semin Radiat Oncol. 2011 Oct;21(4):294-302
pubmed: 21939859
J Nucl Med. 2022 Dec;63(12):1891-1898
pubmed: 35589409
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29
pubmed: 33166497
J Nucl Med. 2021 Feb;62(2):272-279
pubmed: 32591491
J Vasc Interv Radiol. 2022 Jun;33(6):679-686
pubmed: 35219834
J Nucl Med. 2023 Apr;64(4):529-535
pubmed: 36328487
J Nucl Med. 2020 Apr;61(4):608-612
pubmed: 31601696
Semin Intervent Radiol. 2021 Oct;38(4):453-459
pubmed: 34629713
Liver Int. 2019 May;39 Suppl 1:143-155
pubmed: 30843343
J Nucl Med. 2018 Apr;59(4):582-588
pubmed: 28916623
Cancer Treat Rev. 2021 Sep;99:102258
pubmed: 34252720
Cardiovasc Intervent Radiol. 2021 Feb;44(2):345-347
pubmed: 33090248
Actas Dermosifiliogr (Engl Ed). 2021 Jan;112(1):90-92
pubmed: 32891586
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2270-2279
pubmed: 31324943
Semin Nucl Med. 2019 May;49(3):237-243
pubmed: 30954190
Chin Clin Oncol. 2020 Feb;9(1):8
pubmed: 32008330
Semin Intervent Radiol. 2021 Oct;38(4):438-444
pubmed: 34629711
J Hepatol. 2019 Jul;71(1):104-114
pubmed: 30910538